Prognostic role of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with bone metastases

Quirina C.B.S. Thio, W. Alexander Goudriaan, Stein J. Janssen, Nuno Rui Paulino Pereira, Daniel Sciubba, Rachel P. Rosovksy, Joseph H. Schwab

Research output: Contribution to journalArticle

Abstract

Background: Skeletal metastases are a common problem in patients with cancer, and surgical decision making depends on multiple factors including life expectancy. Identification of new prognostic factors can improve survival estimation and guide healthcare providers in surgical decision making. In this study, we aim to determine the prognostic value of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in patients with bone metastasis. Methods: One thousand and twelve patients from two tertiary referral centers between 2002 and 2014 met the inclusion criteria. Bivariate and multivariate Cox regression analyses were performed to determine the association of NLR and PLR with survival. Results: At 3 months, 84.0% of the patients with low NLR were alive versus 61.3% of the patients with a high NLR (p < 0.001), and 75.8% of the patients with a low PLR were alive versus 55.6% of the patients with a high PLR (p < 0.001). Both elevated NLR and elevated PLR were independently associated with worse survival (hazard ratio (HR): 1.311; 95% confidence interval (CI): 1.117–1.538; p = 0.001) and (HR: 1.358; 95% CI: 1.152–1.601; p < 0.001), respectively. Conclusion: This study showed both NLR and PLR to be independently associated with survival in patients who were treated for skeletal metastasis.

Original languageEnglish (US)
JournalBritish Journal of Cancer
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Neutrophils
Blood Platelets
Lymphocytes
Neoplasm Metastasis
Bone and Bones
Survival
Decision Making
Confidence Intervals
Life Expectancy
Tertiary Care Centers
Health Personnel
Regression Analysis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Thio, Q. C. B. S., Goudriaan, W. A., Janssen, S. J., Paulino Pereira, N. R., Sciubba, D., Rosovksy, R. P., & Schwab, J. H. (Accepted/In press). Prognostic role of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with bone metastases. British Journal of Cancer. https://doi.org/10.1038/s41416-018-0231-6

Prognostic role of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with bone metastases. / Thio, Quirina C.B.S.; Goudriaan, W. Alexander; Janssen, Stein J.; Paulino Pereira, Nuno Rui; Sciubba, Daniel; Rosovksy, Rachel P.; Schwab, Joseph H.

In: British Journal of Cancer, 01.01.2018.

Research output: Contribution to journalArticle

Thio, Quirina C.B.S. ; Goudriaan, W. Alexander ; Janssen, Stein J. ; Paulino Pereira, Nuno Rui ; Sciubba, Daniel ; Rosovksy, Rachel P. ; Schwab, Joseph H. / Prognostic role of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with bone metastases. In: British Journal of Cancer. 2018.
@article{e3717cb9c2a14e48b10580667777488c,
title = "Prognostic role of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with bone metastases",
abstract = "Background: Skeletal metastases are a common problem in patients with cancer, and surgical decision making depends on multiple factors including life expectancy. Identification of new prognostic factors can improve survival estimation and guide healthcare providers in surgical decision making. In this study, we aim to determine the prognostic value of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in patients with bone metastasis. Methods: One thousand and twelve patients from two tertiary referral centers between 2002 and 2014 met the inclusion criteria. Bivariate and multivariate Cox regression analyses were performed to determine the association of NLR and PLR with survival. Results: At 3 months, 84.0{\%} of the patients with low NLR were alive versus 61.3{\%} of the patients with a high NLR (p < 0.001), and 75.8{\%} of the patients with a low PLR were alive versus 55.6{\%} of the patients with a high PLR (p < 0.001). Both elevated NLR and elevated PLR were independently associated with worse survival (hazard ratio (HR): 1.311; 95{\%} confidence interval (CI): 1.117–1.538; p = 0.001) and (HR: 1.358; 95{\%} CI: 1.152–1.601; p < 0.001), respectively. Conclusion: This study showed both NLR and PLR to be independently associated with survival in patients who were treated for skeletal metastasis.",
author = "Thio, {Quirina C.B.S.} and Goudriaan, {W. Alexander} and Janssen, {Stein J.} and {Paulino Pereira}, {Nuno Rui} and Daniel Sciubba and Rosovksy, {Rachel P.} and Schwab, {Joseph H.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1038/s41416-018-0231-6",
language = "English (US)",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Prognostic role of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with bone metastases

AU - Thio, Quirina C.B.S.

AU - Goudriaan, W. Alexander

AU - Janssen, Stein J.

AU - Paulino Pereira, Nuno Rui

AU - Sciubba, Daniel

AU - Rosovksy, Rachel P.

AU - Schwab, Joseph H.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Skeletal metastases are a common problem in patients with cancer, and surgical decision making depends on multiple factors including life expectancy. Identification of new prognostic factors can improve survival estimation and guide healthcare providers in surgical decision making. In this study, we aim to determine the prognostic value of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in patients with bone metastasis. Methods: One thousand and twelve patients from two tertiary referral centers between 2002 and 2014 met the inclusion criteria. Bivariate and multivariate Cox regression analyses were performed to determine the association of NLR and PLR with survival. Results: At 3 months, 84.0% of the patients with low NLR were alive versus 61.3% of the patients with a high NLR (p < 0.001), and 75.8% of the patients with a low PLR were alive versus 55.6% of the patients with a high PLR (p < 0.001). Both elevated NLR and elevated PLR were independently associated with worse survival (hazard ratio (HR): 1.311; 95% confidence interval (CI): 1.117–1.538; p = 0.001) and (HR: 1.358; 95% CI: 1.152–1.601; p < 0.001), respectively. Conclusion: This study showed both NLR and PLR to be independently associated with survival in patients who were treated for skeletal metastasis.

AB - Background: Skeletal metastases are a common problem in patients with cancer, and surgical decision making depends on multiple factors including life expectancy. Identification of new prognostic factors can improve survival estimation and guide healthcare providers in surgical decision making. In this study, we aim to determine the prognostic value of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in patients with bone metastasis. Methods: One thousand and twelve patients from two tertiary referral centers between 2002 and 2014 met the inclusion criteria. Bivariate and multivariate Cox regression analyses were performed to determine the association of NLR and PLR with survival. Results: At 3 months, 84.0% of the patients with low NLR were alive versus 61.3% of the patients with a high NLR (p < 0.001), and 75.8% of the patients with a low PLR were alive versus 55.6% of the patients with a high PLR (p < 0.001). Both elevated NLR and elevated PLR were independently associated with worse survival (hazard ratio (HR): 1.311; 95% confidence interval (CI): 1.117–1.538; p = 0.001) and (HR: 1.358; 95% CI: 1.152–1.601; p < 0.001), respectively. Conclusion: This study showed both NLR and PLR to be independently associated with survival in patients who were treated for skeletal metastasis.

UR - http://www.scopus.com/inward/record.url?scp=85052290317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052290317&partnerID=8YFLogxK

U2 - 10.1038/s41416-018-0231-6

DO - 10.1038/s41416-018-0231-6

M3 - Article

C2 - 30116026

AN - SCOPUS:85052290317

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

ER -